Novo-Nordisk extends buyback programme, shares remain a heavyweight in Copenhagen

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 07:22.

Novo-Nordisk (DK0062498333) on June 22 disclosed the latest phase of its share repurchase programme, authorizing buybacks of up to DKK 10 billion in 2026, according to a company press release. The June 22 Globenewswire announcement noted that the shares trade on the Nasdaq Copenhagen exchange and are part of the OMX Copenhagen 25 benchmark.

Details of the new buyback phase

The June 22 Globenewswire filing states that Novo-Nordisk’s board has approved a share repurchase programme of up to DKK 10 billion to be executed between June 24 and November 1, 2026, under the authorization granted at the March 2026 annual general meeting. The official press release adds that the programme will be carried out in compliance with the EU Market Abuse Regulation’s safe harbor provisions.

According to the same disclosure, Novo-Nordisk plans to repurchase both A and B shares as well as American Depositary Receipts listed on the New York Stock Exchange, with transactions executed by a single lead manager who makes trading decisions independently within agreed parameters. The Globenewswire text specifies that the maximum daily volume will not exceed 25 percent of the average daily trading volume of Novo-Nordisk B shares on Nasdaq Copenhagen in the preceding 20 trading days.

Analyst views and index role

MarketScreener data show that Novo-Nordisk is a constituent of the OMX Copenhagen 25, Stoxx Europe 50 and Stoxx Europe 600 indices, underscoring its role as a European large-cap anchor alongside peers such as Novo Nordisk’s Danish rival Lundbeck in the pharmaceuticals space. MarketScreener’s company profile lists diabetes and obesity treatments as the core business segments.

Recent analyst commentary compiled by MarketScreener indicates that Berenberg, Nordea Bank and Deutsche Bank all updated their views on Novo-Nordisk in mid-June, with Berenberg reiterating a Buy rating and lifting its price target to DKK 325, Nordea upgrading to Buy, and Deutsche Bank maintaining Hold with a target of DKK 290. The analyst consensus overview shows that a majority of covering houses currently rate the shares at Buy or equivalent.

How Novo-Nordisk earns its money

Novo-Nordisk generates the bulk of its revenue from diabetes and obesity care, with blockbuster products such as the GLP-1 agonists Ozempic for type 2 diabetes and Wegovy for obesity management, as well as long-acting insulins like Tresiba and NovoRapid in its insulin portfolio. The company’s investor materials also highlight a growing rare disease franchise focused on hemophilia and growth hormone disorders.

Where the shares trade today

The Novo-Nordisk shares (DK0062498333) last traded on Nasdaq Copenhagen at 856.00 Danish kroner at 2026-06-24, 15:30 local time, according to recent exchange data.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities.